Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML-193 (CID 1261822) 是一种有效的选择性GPR55拮抗剂,IC50值为 221 nM,对 GPR55 的选择性比 GPR35、CB1 和 CB2 高 27 倍以上,可改善帕金森病 (PD) 大鼠的运动和感觉运动缺陷。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
2 mg | ¥ 455 | 现货 | ||
5 mg | ¥ 690 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 1,960 | 现货 | ||
50 mg | ¥ 2,920 | 现货 | ||
100 mg | ¥ 4,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 939 | 现货 |
产品描述 | ML-193 (CID 1261822) is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats. |
靶点活性 | GPR55:221 nM |
体外活性 | ML193, a selective GPR55 antagonist.?ML184 significantly promoted neuronal differentiation in vitro while ML193 reduced differentiation rates as compared to vehicle treatment.Continuous administration of O-1602 into the hippocampus via a cannula connected to an osmotic pump resulted in increased Ki67+ cells within the dentate gyrus.?O-1602 increased immature neuron generation, as assessed by DCX+ and BrdU+ cells, as compared to vehicle-treated animals.?GPR55-/- animals displayed reduced rates of proliferation and neurogenesis within the hippocampus while O-1602 had no effect as compared to vehicle controls[2]. |
体内活性 | Intra-striatal administration of ML193 increased time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats mostly at the dose of 1 g/rat[1]. |
别名 | CID 1261822 |
分子量 | 527.59 |
分子式 | C28H25N5O4S |
CAS No. | 713121-80-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (113.72 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8954 mL | 9.4771 mL | 18.9541 mL | 47.3853 mL |
5 mM | 0.3791 mL | 1.8954 mL | 3.7908 mL | 9.4771 mL | |
10 mM | 0.1895 mL | 0.9477 mL | 1.8954 mL | 4.7385 mL | |
20 mM | 0.0948 mL | 0.4739 mL | 0.9477 mL | 2.3693 mL | |
50 mM | 0.0379 mL | 0.1895 mL | 0.3791 mL | 0.9477 mL | |
100 mM | 0.019 mL | 0.0948 mL | 0.1895 mL | 0.4739 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ML-193 713121-80-3 GPCR/G Protein Cannabinoid Receptor Inhibitor deficits motor ML193 CID 1261822 sensorimotor ML 193 G protein-coupled receptor 55 disease Parkinson CID1261822 CID-1261822 inhibit GPR55 inhibitor